Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

The supply shortage and high costs of GLP-1 weight loss drugs have created an opportunity for compounded GLP-1 treatments to ...

A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.

Novo Nordisk A/S NVO reported fourth-quarter 2024 earnings of 91 cents per American Depositary Receipt (ADR), which beat the ...

For its part, Hims & Hers maintains that the 'Sick of the System' ad – its first for a Super Bowl – "highlights the growing ...

It’s estimated 5.3 million Medicare members use the 15 drugs selected today. They account for $41 billion, or 14% of part D spending, from Nov. 1, 2023, to Oct. 31, 2024. GLP-1 drug costs over ...

Novo Nordisk’s weekly GLP-1 diabetes drug Ozempic has been included in formularies ... According to Reuters, Ozempic has been included on a 2018 formulary list of acceptable medicines drawn ...

There are many possible explanations for that, including side effects and the drug’s cost. According to a KFF analysis, the list price for GLP-1 drugs can range between $936 and $1,349 before ...

Consequently, people using GLP-1 medications for weight loss may litigate ... For instance, at the start of 2024, the US list prices of Ozempic (Novo Nordisk) and Mounjaro (Eli Lilly) increased ...

There are many possible explanations for that, including side effects and the drug’s cost. According to a KFF analysis, the list price for GLP-1 drugs can range between $936 and $1,349 before ...

The GLP-1 drugs – I just realised I don’t actually ... put it on the medical shortage list in America. What that means, interestingly enough for very logical reasons, if you are on the list ...